Written by RTTNews.com for RTTNews (RTTNews) - BiomX Inc. (PHGE), a clinical stage biopharmaceutical company, announced that an independent Data Monitoring Committee has completed a safety review of adverse events reported in its Phase 2b trial of BX004 in cystic fibrosis. The independent Data Monitoring Committee has recommended that the study continue with revised dosing. Accordingly, the study protocol will be updated, and topline results are now expected in Q2 2026. BX00

Tobramycin inhalation solution offers affordable option to patients 6 and older by Marisa Wexler, MS The U.S. Food and Drug Administration (FDA) has approved a new generic form of inhaled tobramycin , an antibiotic that’s used to treat bacterial lung infections in people with cystic fibrosis  (CF). The newly approved therapy, tobramycin inhalation solution, will be sold by The Ritedose Corporation through its generics division, Ritedose Pharmaceuticals. It is indicated to tr

Experimental compound 3b addresses disease itself, viral threats by Michela Luciano, PhD | Researchers in Italy have developed a new experimental compound called 3b, which has shown early promise as a dual-action therapy for cystic fibrosis (CF). It addresses the dysfunction of the CFTR protein that causes the disease, as well as protects against viral threats that can worsen lung problems. In lab tests, compound 3b restored CFTR activity, blocked the growth of several resp